Q4 updates from Conference call

0.0250 (0.00%)View full PRR report with
  1. 29

    Will report the immune monitoring profile of all 63 patients during the upcoming quarter. Have 44 clinical centers that have been activated by Prima. Their goal is to initiate clinical trial sites and commence patient recruitment for these trials towards the end of 2013 or early in 2014.

    Received approximately AU$1.7 billion in government grants of R&D tax incentive in the financial year. Cash outflows during the quarter for research and development was about AU$2.75 million.


  2. 348

    Expect a good run up to results on 1st October.

    Wouldn't surprise me to see the SP double if not triple over the next 6 weeks :wink:

  3. 348

    Used to be one of the most controversial stocks on this site, now hardly discussed. Strange given we are so close to imperative data on Cvac. 12 trading days until CAN003 trial results, ICS data due any day now.

    Good luck holders


Your browser is too old for TopStocks and not secure. Please update your browser